Reuters logo
BRIEF-Idera Pharmaceuticals advances investigational treatment for unmet need in anti-PD-1 refractory metastatic melanoma
April 11, 2017 / 11:26 AM / 6 months ago

BRIEF-Idera Pharmaceuticals advances investigational treatment for unmet need in anti-PD-1 refractory metastatic melanoma

April 11 (Reuters) - Idera Pharmaceuticals Inc

* Idera Pharmaceuticals advances investigational treatment – intratumoral IMO-2125 in combination with ipilimumab - for unmet need in anti-PD-1 refractory metastatic melanoma

* Idera Pharmaceuticals Inc - Enrollment has begun for phase 2 portion of trial with 8mg dose of intratumoral IMO-2125

* Idera Pharmaceuticals Inc - Phase 1 dose escalation of IMO-2125 in combination with pembrolizumab is ongoing

* Idera Pharmaceuticals - In addition to potential interim updates, expects to have overall response rate data from IMO-2125 trial available in Q1 of 2018

* Idera Pharma - To continue discussions with regulatory authorities for path to registration for IMO-2125 with ipilimumab in certain melanoma patients Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below